Vaccines and the Infectious Diseases They Prevent

Image representing the teeth of a bat with IMOVAX RABIES and IMOGRAM RABIES-HT writen below

Immunogenicity (Antibody Response)

IMOGAM Rabies–HT Immune Globulin is used to provide immediate, short-term protection against rabies¹

The recommended post-exposure dose of 20 IU/mL of IMOGAM Rabies–HT Immune Globulin provides maximum levels of rabies antibodies within 24 hours with minimum interference to the immune response to subsequent doses of IMOVAX Rabies vaccine^1-3

Who needs IMOGAM Rabies–HT Immune Globulin and when? Learn more NOW!

View full Prescribing Information for IMOGAM Rabies–HT Immune Globulin.

References: 1. Centers for Disease Control and Prevention (CDC). Human rabies prevention—United States, 1999: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1-21. 2. Loofbourow JC, Cabasso VJ, Roby RE, Anuskiewicz W. Rabies immune globulin (human): clinical trials and dose determination. JAMA. 1971;217:1825-1831. 3. Lang J, Gravenstein S, Briggs D, et al. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. Biologicals. 1998;26:7-15.

IMOVAX® Rabies

Indication

IMOVAX Rabies vaccine is indicated for active, pre- and post-exposure immunization against rabies.

Safety Information
The most common local and systemic adverse reactions to IMOVAX Rabies vaccine may include injection site pain, erythema, and swelling; headache, nausea, and muscle aches. Other adverse reactions may occur. Once initiated for post-exposure treatment rabies vaccination should not be interrupted or discontinued because of mild local or systemic adverse reactions. Usually such reactions can be successfully managed with anti-inflammatory and antipyretic agents. Vaccination with IMOVAX Rabies vaccine may not protect all individuals.

Before administering IMOVAX Rabies vaccine, please see accompanying full Prescribing Information.

IMOGAM® Rabies–HT

Indication
IMOGAM Rabies-HT immune globulin is given for passive immunization of individuals suspected of exposure to rabies.

Safety Information
Side effects to the IMOGAM Rabies-HT immune globulin include injection site tenderness, pain, and muscle soreness or stiffness. Other side effects may occur. IMOGAM Rabies-HT immune globulin should not be given in repeated doses once vaccine treatment has begun. IMOGAM Rabies-HT immune globulin is made from components of human blood and, therefore, this vaccine may carry a risk of transmitting infectious material, although careful selection of donors and extensive testing are intended to minimize this risk. Treatment with a rabies immune globulin may not protect all individuals.

For more information about IMOGAM Rabies-HT immune globulin, talk to your health-care professional.

Last modified: 5/2/08